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Certain strains of the soil microorganism Streptomyces produce an antibiotic, fosfomycin [(1 R,2 S)-
epoxypropylphosphonic acid], which is effective against both Gram-positive and Gram-negative
pathogens by inhibiting the ﬁrst committed step in cell-wall biosynthesis. Fosfomycin resistance
proteins are metallo-enzymes that are known to inactivate the antibiotic by the addition of
nucleophiles such as water, glutathione (GSH), L-cysteine and bacillithiol (BSH) to the oxirane ring
of the molecule. Progress in the characterisation of FosB-type fosfomycin resistance proteins found
in many Gram-positive organisms has been slow. This paper provides a brief description of the
diversity of fosfomycin resistance proteins in general and, more speciﬁcally, new data characteris-
ing the substrate selectivity, structure, mechanism and metal-ion dependence of FosB enzymes
from pathogenic strains of Staphylococcus and Bacillus. These new ﬁndings include the high-
resolution X-ray diffraction structures of FosB enzymes from Staphylococcus aureus and Bacillus
cereus in various liganded states and kinetic data that suggest that Mn(II) and BSH are the preferred
divalent cation and thiol substrate for the reaction, respectively. The discovery of the inhibition of
the enzyme by Zn(II) led to the determination of a ternary structure of the FosB  Zn(II) 
fosfomycin  L-Cys complex which reveals both substrates present in a pose prior to reaction.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Contents
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Since the introduction of antibiotic compounds for the
treatment of infectious diseases, mankind has enjoyed a
historically unprecedented increase in life expectancy and
overall quality of life. However, the pathogens that cause
these infectious diseases adapt quickly, and as a result,
many of the antibiotic compounds once used to treat
infections are quickly becoming ineffective. Currently,
there exist numerous pathogenic bacteria that are resistant
to multiple drugs. While the exact mechanism of antibiotic
resistance can vary, the primary means of bacterial survival
are: (1) decreased cell permeability for the antibiotic, (2)
active efﬂux pumping of the antibiotic out of the cell, and
(3) destruction/inactivation of the compound via antibiotic
modifying enzymes (Arias and Murray, 2009). Antibiotic
modifying enzymes represent the most common mode of
microbial resistance and are, therefore, obvious targets for
the development of new therapeutic agents.
Fosfomycin, or (1R,2S)-epoxypropylphosphonic acid, is a
broad-spectrum antibiotic produced by certain strains of the
soil microorganism Streptomyces (Falagas et al., 2008; Patel
et al., 1997). It is effective against both Gram-negative and
Gram-positive bacteria, including numerous human pathogens.
Fosfomycin inhibits cell wall biogenesis by inactivating the
enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase,
also known as MurA. The MurA enzyme catalyses the ﬁrst
committed step in peptidoglycan biosynthesis, namely the
ligation of phosphoenolpyruvate to the 3'-hydroxy group of
UDP-N-acetylglucosamine. This pyruvate moiety is further
reduced by UDP-N-acetylenolpyruvoylglucosamine reductase
(MurB) in the presence of NADPH and ultimately provides the
linker that bridges the glycan and peptide portions of pepti-
doglycan. Fosfomycin is a phosphoenolpyruvate analogue that
irreversibly inhibits MurA by alkylating an active site cysteine
residue that acts as a general base during catalysis (Eschenburg
et al., 2003, 2005; Krekel et al., 2000).
Fosfomycin was initially characterised in 1969 (Hendlin
et al., 1969; Stapley et al., 1969) and is used in the United
States under the trade name Monurol. Taken within appro-
priate dosing recommendations, the drug is well tolerated,
has a low incidence of harmful side effects and is eliminated
in its unmetabolised, active form (Patel et al., 1997). It is
most often prescribed as a single three gram oral dose for
the treatment of certain urinary tract infections. The large
dose results in very high concentrations of the active drug in
the urine and thus circumvents two of the primary bacterial
resistance mechanisms: decreased cell permeability and
active efﬂux pumping. When combined with other antibac-
terial drugs, it has been effective against various antibiotic-
resistant strains. Shortly after the introduction of fosfomy-
cin, however, bacterial strains containing fosfomycin mod-
ifying enzymes began to emerge.There are currently three distinct classes of fosfomycin
resistance enzymes (FosA, FosX, and FosB) all of which
belong to the Vicinal Oxygen Chelate (VOC) superfamily of
metalloenzymes. They are structurally characterised by a
3D domain-swapped arrangement of tandem βαβββ motifs in
which both subunits of the homodimer participate in
coordination of a metal ion and formation of the active
sites (Figure 1). FosA enzymes are Mn2+ and K+ dependent
glutathione-S-transferases that catalyse nucleophilic addi-
tion of glutathione (GSH) to carbon-1 of fosfomycin, opening
the epoxide ring of the antibiotic and resulting in a modiﬁed
compound with no bactericidal properties (Arca et al.,
1990, 1988; Bernat et al., 1997, 1999). Genes encoding
FosA have been identiﬁed in several Gram-negative bacter-
ial species including the opportunistic human pathogen
Pseudomonas aeruginosa (Rife et al., 2002). FosX enzymes,
also from Gram-negative bacterial species, are Mn2+ depen-
dent hydrolases that catalyse the hydration of fosfomycin at
carbon-1 forming a vicinal diol and inactivating the anti-
biotic (Fillgrove et al., 2007, 2003). FosB enzymes were
later discovered in Gram-positive organisms such as Strep-
tomyces aureus, Bacillus cereus, and Bacillus subtilis (Cao
et al., 2001; Rigsby et al., 2005; Thompson et al., 2013) and
catalyse the Mn2+ dependent addition of L-cysteine (L-Cys)
or bacillithiol (BSH) to carbon-1 of fosfomycin (Thompson
et al., 2013; Lamers et al., 2012).
FosA
FosA was initially discovered as a plasmid-borne resistance
gene isolated from clinical samples of Serratia marcescens
(García-Lobo and Ortiz 1982). This gene encodes a 16 kDa
protein that adds glutathione to carbon-1 of fosfomycin,
opening the epoxide ring as indicated in Figure 1. This
modiﬁcation of the antibiotic results in a compound with no
bactericidal properties, as it is no longer a suitable electro-
phile for the active site cysteine residue of MurA. Thus, FosA
enzymes are Mn+2-dependent glutathione-S-tranferases of
the VOC superfamily. Their activity is signiﬁcantly enhanced
in the presence of K+ or other monovalent cations (Beharry
and Palzkill 2005). Genes encoding FosA enzymes have been
identiﬁed in other Gram-negative bacterial species includ-
ing the opportunistic human pathogens Pseudomonas aeru-
ginosa (Rigsby et al., 2007), Klebsiella pneumoniae and
Acinetobacter baumannii.
FosX
A probe of nucleotide sequence databases revealed another
class of fosfomycin resistance enzymes, termed FosX
(Fillgrove et al., 2007). The FosX enzymes share 30–35%
nucleotide sequence identity with the FosA enzymes, but
Figure 1 Top: Overall structures of FosA (PDB 1LQP) (Rife et al., 2002), FosB (PDB 4JH6) (Thompson et al., 2013), and FosX (PDB
1R9C) (Fillgrove et al., 2003). Bottom: Reactions catalysed by fosfomycin resistance enzymes.
19Diversity in fosfomycin resistance proteinscatalyse the hydration of fosfomycin at carbon-1, as shown
in Figure 1. The hydrolase reaction opens the epoxide ring
and forms a vicinal diol with no bactericidal properties in
the same manner as FosA. FosX enzymes do not require
monovalent cations for optimal activity. Genes encoding
FosX have been found in numerous Gram-negative bacterial
species including Listeria monocytogenes, Mesorhizobium
loti, and Clostridium botulinum.
The FosX enzyme from M. loti (FosXMl) demonstrates
catalytic promiscuity and is able to perform both fosfomycin
glutathione transferase (FosA) and fosfomycin hydrolase
(FosX) reactions as might be expected given the relationship
to Gram-negative bacteria. However, the enzyme performs
both of these reactions with markedly reduced catalytic
efﬁciencies, and as a result, FosXMl does not confer
appreciable fosfomycin resistance. For this reason it is
likely that FosXMl actually functions in phosphonate meta-
bolism and is an evolutionary precursor to true fosfomycin
resistance enzymes (Fillgrove et al., 2003; O'Brien and
Herschlag, 1999).
FosB
A third, distinct fosfomycin resistance factor, FosB, was
later discovered in Gram-positive organisms such as S.
aureus, B. cereus and B. subtilis (Cao et al., 2001; Rigsby
et al., 2005; Thompson et al., 2013). These are genomically
encoded fosfomycin resistance enzymes that are also mem-
bers of the VOC metalloenzyme superfamily. However, FosB
enzymes are not glutathione-S-transferases like FosA or
hydrolases like FosX. Rather, FosB enzymes catalyse the
Mn+2-dependent addition of bacillithiol (BSH) or L-cysteine
(L-Cys) to carbon-1 of fosfomycin (Figure 1) (Cao et al.,
2001). The end result is a similar, chemically modiﬁed
inactive form of the antibiotic. Glutathione is not found in
Gram-positive bacteria and thus explains why the FosB
enzymes have not evolved to be glutathione-transferases.
Instead, BSH is the abundant low-molecular-weight thiol
found in nearly equal concentrations as L-cysteine. BSH is
the α-anomeric glycoside of L-cysteinyl-D-glucosaminyl-L-
malate. It was ﬁrst isolated and identiﬁed in 2009 from S.aureus and Deinococcus radiodurans (Figure 2) (Newton
et al., 2009). Similar to the function of mycothiol in
mycobacteria, BSH serves as a substitute for glutathione
in Gram-positive organisms (Gaballa et al., 2010). Recent
kinetic analyses of the FosB enzymes from multiple Gram-
positive organisms have indicated that BSH is the preferred
thiol substrate over L-Cys when activated by Mn(II) (Figure
2) (Thompson et al., 2013; Lamers et al., 2012; Roberts
et al., 2013; Thompson et al., 2014), catalysing addition of
the cysteinyl-moiety of BSH to carbon-1 of fosfomycin
similar to FosA addition of GSH. In addition, Zn2+ is a
potent inhibitor of FosB for either BSH or L-Cys transferase
activity. Both BSH and FosB knockout/null cells exhibit a
signiﬁcant increase in their sensitivity to fosfomycin (Figure
2; Thompson et al., 2014). These results have led to the
FosB enzymes being characterised as bacillithiol-S-
transferases.
Mechanism of fosfomycin inactivation
The structural data for FosB in particular is extensive and
has provided the most insight into the mechanism of action
of the VOC superfamily of fosfomycin resistance enzymes.
There are a total of nine deposited structures for FosB from
B. cereus (FosBBc) (Thompson et al., 2013) and ﬁve for FosB
from S. aureus (Thompson et al., 2014). Together, they
provide detailed information about how the FosB enzymes
function.
For FosBBc, the three most informative structures were
the FosBBc Mn(II)  Fosfomycin structure (PDB 4JH6), the
FosBBc Mn(II)  L-Cys-Fosfomycin product structure (PDB
4JH7), and the FosBBc  Zn(II)  Fosfomycin and L-Cys ternary
structure (PDB 4JH8) (Thompson et al., 2013). Comparison
of the FosBBc Mn(II)  Fosfomycin and FosBBc Mn(II)  L-Cys-
Fosfomycin product structures revealed a unique trigonal
bipyramidal metal-ligand coordination geometry (Figure 3).
Formation of the product relieves strain on the atomic
orbitals of the metal and ring strain in the epoxide of the
antibiotic. In addition, the unique coordination geometry
explains why the VOC metalloenzymes are activated by Mn
(II) and inhibited by Zn(II). The highest symmetry axis places
Figure 2 Upper: Structure of bacillithiol (Left). Time course of FosBSa catalysed-addition of BSH or L-Cys to fosfomycin in the
presence of Mn2+ or Zn2+ (Right). Reactions were carried out at 25 1C in 20 mM HEPES, pH 7.0 with 4 mM fosfomycin and 0.50 mM
enzyme in the presence of ( ) 1.6 mM BSH and 10 mM Mn2+, ( ) 1.6 mM BSH and 10 mM Zn2+, ( ) 1.6 mM BSH, 10 mM Mn2+,
and 100 mM Zn2+, (■) 1.8 mM L-Cys and 10 mM Mn2+, ( ) 1.8 mM L-Cys and 10 mM Zn2+ or ( ) 1.8 mM L-Cys, 10 mM Mn2+, and
100 mM Zn2+. Botton: Fosfomycin disk diffusion assays for MRSA (JE2). The amount off fosfomycin on each disk is shown in red. (Left)
Wild type MRSA. (Center) BSH knockout MRSA. (Right) FosB knockout MRSA. The zone of clearing for the knockout strains has
doubled. (Figures adapted from (Choi et al., 2012)).
Figure 3 (Left) Comparison of the FosBBc Mn(II)  Fosfomycin  (PDB 4JH6) and (Center) FosBBc Mn(II)  L-Cys-Fosfomycin  (PDB
4JH7) structures. If the Z-axis is deﬁned along E115Oε–Mn(II)–FosfomycinO(Oxirane), there is a distorted trigonal bipyramidal geometry
about the Mn(II) center. When the product is formed, the equatorial distances lengthen, and the metal-oxygen(oxirane) bond shortens,
effectively creating a more symmetric trigonal bipyramidal geometry around Mn(II) and relieving strain on both the atomic orbitals
of the metal and the epoxide ring of the antibiotic (Thompson et al., 2013). (Right) Activation of fosfomycin (FosBBc Mn(II) 
Fosfomycin, PDB 4JH6) occurs through σ donation of the epoxide lone pair into the dz2 orbital of Mn(II), increasing the polarity of the
carbon-1-O(Oxirane) bond and resulting in a partial positive charge (δ+) on carbon-1. Furthermore, the inherent electron withdrawing
nature of the phosphonate group will further enhance δ+ on carbon-1 through polarisation of the carbon-1-P bond. The arrows
denote electron charge redistribution away from carbon-1 to both the phosphonate and the epoxide oxygen. This prepares the
antibiotic for nucleophilic attack by the incoming thiolate. (Figure adapted from (Thompson et al., 2013)).
M.K. Thompson et al.20a lone pair of the oxirane oxygen in the position to form a σ-
type interaction with the dZ
2 orbital of the active site metal
ion. Mn(II) is a d5 transition metal species and can acceptelectron density from the lone pair into the dZ
2 orbital. Zn(II)
is a d10 transition metal species and therefore has a full dZ
2
orbital that cannot accept electron density from the
Figure 4 Superposition of the FosBBc Mn(II)  L-Cys-Fosfomycin product structure (PDB 4JH7) and the FosBBc Zn(II)  Fosfomycin and
L-Cys ternary structure (PDB 4JH8). The positions of all other amino acids stay the same, but Asn50 in the ternary complex is rotated
approximately 90 degrees relative to the product complex. Rotation of Asn50 about the Cβ–Cγ bond is the only signiﬁcant difference
observed in the reported structures of FosBBc.
Figure 5 (Left) Apo FosBSa (PDB 4NB2) with the binding loop
in the open conformation. (Right) FosBBc Mn(II)  Fosfomycin
(PDB 4JH6) with the binding loop in the closed conformation.
Closure of the loop surrounds the polar phosphonate end of
fosfomycin with multiple hydrogen bonding interactions and
locks the antibiotic in a position at the bottom of a solvent
channel where the thiolate enters to attack carbon-1. Closure
of the loop also forms the ﬁnal side of the BSH binding cavity on
the surface of the enzyme.
21Diversity in fosfomycin resistance proteinscoordinated antibiotic. Sigma donation of electron density
from the oxirane oxygen of the antibiotic into the dZ
2 atomic
orbital of the metal plays a large role in generating the
partial positive charge (δ+) of carbon-1 of fosfomycin,
activating the antibiotic for nucleophilic attack by the
incoming L-Cys or BSH molecule (Figure 3).
Examination of the FosBBc  Zn(II)  Fosfomycin and L-Cys
ternary structure revealed the only amino acid that under-
goes any signiﬁcant change in any of the deposited FosBBc
structures. Asn50 in the the FosBBc  Zn(II)  Fosfomycin and L-
Cys ternary structure is rotated 90 degrees relative to the
FosBBc Mn(II)  Fosfomycin or FosBBc Mn(II)  L-Cys-Fosfomy-
cin product structures indicating that Asn50 likely has an
important functional role in the mechanism of the FosB
enzymes (Figure 4). Asn50 is a conserved amino acid among
the FosB enzymes and is believed to stabilise both thepositive charge generated on carbon-1 of the antibiotic and
the negatively charged incoming thiolate.
Finally, three of the ﬁve deposited structures of FosBSa
(PDB entries 4NB0, 4NB1, and 4NB2) show a highly con-
served active site loop region of the FosB enzymes in an
open conformation relative to all of the deposited FosBBc
structures. The loop region is now believed to function as a
door that can open and close to allow fosfomycin to enter
the active cavity of the enzyme (Figure 5). Closure of the
door surrounds the polar phosphonate end of fosfomycin
with multiple hydrogen bonding interactions and locks the
antibiotic in a position at the bottom of a solvent channel
where the thiolate enters to attack carbon-1. In addition,
closure of the door forms the ﬁnal side of the BSH binding
cavity on the surface of the enzyme. Interaction of the
glucosaminyl-L-malate domain of BSH with the amino acid
residues of the binding cavity is important for substrate
recognition and is a thermodynamic driving force in the
preference of BSH over L-Cys for the FosB enzymes
(Thompson et al., 2013; Roberts et al., 2013). That fosfo-
mycin must bind for the door to close and form the BSH
binding cavity is consistent with published “order of addi-
tion” kinetic experiments for FosB (Roberts et al., 2013).
In summary, the mechanism of fosfomycin inactivation for
the VOC fosfomycin resistance enzymes can be charac-
terised as acid-catalysed nucleophilic epoxide ring opening.
During attack of carbon-1 of fosfomycin, Mn(II) serves as the
Lewis acid to facilitate the partial positive charge build up
on carbon-1. In FosX, a glutamate residue (Glu44) acts as a
general base in the direct addition of water to the
antibiotic, whereas in FosA and FosB, Tyr39 is proposed to
be in the tyrosinate form stabilised by an adjacent arginine
residue. The tyrosinate form of Tyr39 can then deprotonate
the incoming respective thiol substrate. In FosB, Asn50 is in
an excellent position to stabilise the negatively charged
incoming thiolate and the positive charge on the antibiotic
just before nucleophilic addition occurs (Figure 3). The
ternary structure of FosB with both co-substrates in the
active site (PDB 4JH8) clearly demonstrates this mechanistic
arrangement. In FosA, Ser50 probably serves the function of
stabilising the partial positive charge on the antibiotic, but
lack of a FosA structure with bound glutathione makes it
difﬁcult to infer which residues may play a role in
Figure 6 31P NMR can be used to detect fosfomycin or the L-
Cys-fosfomycin product.
M.K. Thompson et al.22stabilisation of the incoming thiolate. In any case, inversion
of conﬁguration of carbon-1 of the antibiotic indicates that
the reaction proceeds via direct SN2 addition of the
nucleophile for all of the VOC superfamily fosfomycin
resistance enzymes.Moving forward
Just as the FosA enzymes from Gram-negative bacteria have
evolved optimum activity towards GSH and the FosB enzymes
from Gram-positive bacteria have evolved optimum activity
towards BSH, the Mycobacterium species may have evolved a
similar enzyme that most likely utilises mycothiol (MSH). A
recent BLAST search of nucleotide databases has revealed the
ﬁrst likely candidate from Mycobacterium abscessus subspecies
bolletii, FosMMb. This gene represents the ﬁrst of its type found
in any Mycobacterium species and would constitute a fourth
class of VOC fosfomycin resistance enzyme.
FosMMb is a putative fosfomycin resistance enzyme from
Mycobacterium abscessus subspecies bolletii. The complete
genome of M. abscessus subsp. bolletii was reported in March
2012 (Choi et al., 2012). M. bolletii was ﬁrst isolated in 2006
from patients with chronic pneumonia and cystic ﬁbrosis
(Adékambi et al., 2006). It is highly pathogenic and is an
increasing cause of human pulmonary disease and infections of
the skin and soft tissue (Koh et al., 2009; Zelazny et al., 2009).
Furthermore, M. bolletii has been shown to be resistant to
clarithromycin, a standard drug of choice for the treatment of
respiratory tract infections. FosMMb is a 134 amino acid protein
that shares 32% sequence identity with FosBSa and maintains
nearly every amino acid found in the active site of the FosA or
FosB enzymes. The gene encoding FosMMb has been synthesised
and inserted into a standard pETexpression vector. The protein
has been expressed, puriﬁed, and preliminarily tested for thiol
transferase activity. The preliminary results indicate that, like
FosB, FosMMb has L-Cys transferase activity to fosfomycin
(Figure 6). Furthermore, preliminary results indicate that
FosMMb does not possess GSH or BSH transferase activity. Taken
together, these results suggest that FosMMb will in fact be a
mycothiol-S-transferase.Variety is the price of life
Diversiﬁcation of function in the VOC superfamily of fosfo-
mycin resistance enzymes indicates that this particular
resistance mechanism to the antibiotic had to have devel-
oped prior to the evolutionary split of Gram-positive, Gram-
negative, and Mycobacterium species. The variety of
mechanisms is then a result of the availability of the native
nucleophile for the individual organisms. Inactivation of
fosfomycin still occurs via the same regioselective acid-
catalysed, SN2-type epoxide ring opening reaction mechan-
ism that depends on the native nucleophile in each organ-
ism. Thus, with respect to the evolution of microbial
resistance to fosfomycin, variety is not just the price of
life; it is the requirement for survival.
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